PRESS RELEASES

JJP Biologics obtains positive in vivo preclinical melanoma data and continues development of JJP-1008, a first-in-class anti-CD270 checkpoint inhibitor

JJP Biologics confirms the mechanism of action and immunostimulatory activity of JJP-1008, a potential first-in-class therapeutic anti-CD270 monoclonal antibody. JJP-1008 selectively inhibits the immunosuppressive activity…

JJP Biologics announces initiation of the Multiple Ascending Dose (MAD) part of its Phase I Clinical Trial for JJP-1212

JJP Biologics announces the start of the MAD part in the ongoing Phase I Clinical Trial of a new investigational medicinal product JJP-1212, a first-in-class…

JJP Biologics announces initiation of the development of an active substance & drug product manufacturing process for a first-in-class anti-CD270 monoclonal antibody…

JJP Biologics announces initiation of the development of an active substance & drug product manufacturing process for a first-in-class anti-CD270 monoclonal antibody (JJP-1008) aimed at…

JJP Biologics announces positive recommendation of Dose Escalation Committee to next dose level of its ongoing Phase I Clinical Trial of JJP-1212

JJP Biologics announces a positive recommendation from the Phase I Dose Escalation Committee to move to second cohort in the ongoing single ascending dose (SAD)…

JJP Biologics announces positive decision to execute a First-in-Human clinical trial of anti-inflammatory mAb JJP-1212 (anti-CD89)

JJP Biologics has received a positive conclusion on the Clinical Trial Application assessment for a Phase I Study of a potential first-in-class anti-CD89 antagonist, JJP-1212…

JJP Biologics opens its own research laboratory in Poland

JJP Biologics acquires Recepton’s R&D facilities and antibody-engineering/ production expertise, strengthening discovery and R&D capabilities to support the growing innovative pipeline. March 27, 2024 Warsaw,…